Skip to main content
PLOS One logoLink to PLOS One
. 2026 Jul 27;21(7):e0354277. doi: 10.1371/journal.pone.0354277

Image-based identification and DEA-based optimization modeling of antibiotic packaging using unsupervised learning techniques

Phakdee Sukpornsawan 1, Yutthapoom Meepradist 1, Titinun Auamnoy 1, Ureerat Suksawatchon 2, Somchart Chokchaitam 3, Suthabordee Muongmee 1,*
Editor: Renier Mendoza4
PMCID: PMC13405083  PMID: 42507753

Abstract

Background

Ensuring medication safety requires accurate identification of antibiotic packaging, especially within pharmacy automation and dispensing systems. Advanced imaging and machine learning offer novel avenues for physical package recognition.

Objective

To investigate visual and textual features of antibiotic packages and evaluate their relationship with identification outcomes using unsupervised learning and efficiency-based analysis.

Methods

Thirty-six antibiotic formulations from Thailand (2016–2021) were analyzed using binary imaging, entropy metrics, packaging area ratio (PAR), and optical character recognition (OCR). K-means clustering was applied to segment package groups, and data envelopment analysis (DEA) was used to assess relative efficiency without assuming predefined functional relationships between inputs and outputs.

Results

Nine distinct image clusters were identified. Packages with mid-range entropy (7.1–7.5) and PAR (1.2–1.45) were associated with higher identification consistency. OCR text confidence influenced identification outcomes. DEA identified clusters with relatively efficient input–output configurations.

Conclusion

Integrating image-derived metrics and OCR-based features supports automated antibiotic package identification. This framework provides a structured approach for evaluating packaging characteristics in pharmacy workflows.

1. Introduction

Medication safety remains a persistent challenge in contemporary healthcare systems, particularly as pharmacy workflows increasingly rely on automation, high-throughput dispensing, and distributed supply chains [1,2]. Although digital technologies have improved prescription processing and inventory management, verification tasks at the point of dispensing often still depend on rapid visual assessment of pharmaceutical products. This reliance on visual inspection introduces vulnerability within automated workflows, especially in settings characterized by high workload, heterogeneous product sourcing, and non-standardized packaging designs [3].

Antibiotics represent a critical medication category within this context. They are among the most frequently dispensed medicines worldwide and are closely associated with patient safety, antimicrobial stewardship, and the global burden of antimicrobial resistance (AMR) [1–3]. In many low- and middle-income countries, including Thailand, antibiotic markets are dominated by generic products from multiple manufacturers, often displaying visually similar packaging with variable print quality, reflective materials, and inconsistent layout conventions [4–6]. Such characteristics increase the likelihood of look-alike packaging confusion and complicate digital verification processes in pharmacy practice.

Recent advances in computer vision and artificial intelligence have enabled automated identification of pharmaceutical products based on visual characteristics. Prior studies have largely focused on pill-level recognition using features such as shape, color, imprint, and surface texture [7,8]. While these approaches demonstrate promising performance under controlled conditions, their applicability is limited in routine pharmacy workflows, where medicines are commonly handled and verified in their packaged form rather than as isolated dosage units. Packaging-level identification therefore represents a complementary but less explored domain within medication safety informatics.

Optical character recognition (OCR) has been widely adopted to extract alphanumeric information from documents and labels and has been applied in pharmaceutical contexts such as batch code reading and regulatory verification [9,10–13]. However, OCR performance is sensitive to surface reflectivity, background noise, and print quality—factors that vary substantially across antibiotic packaging types. When applied in isolation, OCR may exhibit unstable performance in heterogeneous packaging environments, highlighting the need for analytical frameworks that integrate textual confidence with physical packaging characteristics.

Unsupervised learning methods, including clustering techniques, offer a data-driven means of exploring latent structure in heterogeneous image datasets without reliance on predefined labels. Such approaches are particularly suitable when ground truth labels are incomplete or inconsistently defined [14–16]. However, clustering alone does not provide a principled mechanism for evaluating how different feature configurations support identification outcomes. Consequently, a methodological gap remains between exploratory image analysis and decision-oriented evaluation in packaging-level identification studies.

Data Envelopment Analysis (DEA), a non-parametric optimization method traditionally used for efficiency benchmarking, offers a potential approach for addressing this gap. DEA enables comparative efficiency assessment without assuming predefined functional relationships between inputs and outputs, meaning that no specific mathematical form is imposed on how input variables are transformed into outputs. Although DEA has been applied in healthcare operations and pharmaceutical manufacturing, its use as an evaluation layer within image-based packaging identification frameworks remains limited.

Key image-based metrics considered in this study include entropy as a descriptor of surface texture, packaging area ratio (PAR) as a spatial normalization measure, and OCR-derived confidence metrics reflecting text readability.

Against this background, the present study examines how physical and textual features of antibiotic packaging interact to influence automated identification outcomes within a unified analytical framework. Rather than proposing a supervised classification or prediction model, this work adopts a packaging-level informatics perspective that integrates image-derived descriptors, OCR-based confidence metrics, unsupervised clustering, and DEA-based efficiency evaluation.

Specifically, this study analyzes 36 commonly used antibiotic packages in Thailand, characterizing their packaging area ratio, entropy-based texture descriptors, and OCR confidence measures. K-means clustering is employed to explore latent structural groupings, while DEA is applied as a comparative evaluation layer to benchmark feature configurations under fixed analytical assumptions.

The contribution of this study is threefold. First, it shifts the focus of automated drug identification from pill-level imagery to packaging-level analysis, reflecting real-world pharmacy workflows. Second, it introduces a hybrid feature space that combines physical packaging descriptors and OCR confidence metrics to characterize machine-readability in heterogeneous packaging environments. Third, by embedding these features within a DEA-based evaluation framework, the study provides a structured and reproducible approach for comparative analysis without relying on predictive performance claims.

2. Materials and methods

To examine automated antibiotic package identification within real-world pharmacy dispensing workflows, this study employed a structured, multi-stage informatics pipeline. The methodological design follows a sequential logic of physical image capture, feature abstraction, structural grouping, and efficiency evaluation. High-resolution package images were acquired and normalized to reduce acquisition bias. Image-derived physical features and OCR-based textual confidence metrics were then extracted to characterize machine-readability. Unsupervised clustering was applied to explore latent packaging structures without imposing predefined labels, while Data Envelopment Analysis (DEA) was used as an analytical evaluation layer to benchmark the relative efficiency of different feature profiles in supporting correct antibiotic identification. This staged design assigns a distinct and interpretable role to each analytical component within the overall framework.

2.1. Imaging Protocol

High-resolution images of commercial antibiotic packages were captured under controlled laboratory conditions (25 ± 1 °C; 55 ± 5% RH) using three device types to reflect diverse operational settings: (1) a full-frame DSLR camera (Nikon D750, 24 MP, Japan) equipped with a 60 mm macro lens, (2) a document camera (Joyusing V500S, 8 MP, China), and (3) a smartphone (Samsung S20, 12 MP, South Korea). All devices were mounted within a custom-built LED lightbox providing uniform, glare-free illumination (950 ± 50 lx), verified using a calibrated lux meter (Uni-Trend UT383, China). White balance was fixed at 6500 K using a 24-patch color chart (Spyder Checkr 24, Datacolor, Germany), and RGB primaries were referenced to CIE standard wavelengths [17,18]. Annotation monitors were color-profiled using a Spyder5 ELITE sensor to maintain display consistency during labeling and inspection [19].

2.2. Pre-processing Pipeline

Raw images were archived on a local network-attached storage system (ZyXEL NAS326, China). A four-stage image-processing pipeline was applied to detect and isolate regions of interest (ROI) corresponding to antibiotic packaging:

Step 1: ROI Detection. A pretrained YOLOv5 deep-learning model [20] was used to identify and crop rectangular regions containing blister or strip packs. Bounding boxes were resized to 512 × 512 pixels for standardization.

Step 2: Edge Detection and Thresholding. Canny edge detection followed by Otsu’s thresholding was applied to generate binary masks emphasizing edge clarity and contrast [21].

Step 3: Noise Filtering. Median filtering with a 3 × 3 kernel was used to remove salt-and-pepper noise while preserving OCR-relevant edges.

Step 4: Image Normalization. Cropped ROIs underwent histogram stretching for contrast enhancement, yielding high-contrast representations suitable for subsequent text and structural analysis [22].

Representative visual outputs from each processing stage are shown in Fig 1.

Fig 1. Flowchart illustrating the image pre-processing pipeline for antibiotic packaging analysis, comprising YOLOv5-based detection, edge extraction and thresholding, median noise filtering, and histogram normalization.

Fig 1

2.3. Feature engineering

2.3.1. Packaging area ratio (PAR).

Packaging Area Ratio (PAR) was introduced as a normalization metric to account for variations in package size and image scale across heterogeneous antibiotic products. PAR functions as a design-relevant indicator of spatial consistency, enabling fair comparison of packaging layouts under automated visual inspection. By normalizing the primary packaging area against a standardized reference frame, PAR reduces size-induced bias in both image entropy and OCR-derived features.

Foreground pixels were extracted from binary masks to quantify the primary packaging area (PPA). A fixed-size reference object defined the standard drive area (SDA), corresponding to the pixel area of a credit-card-sized card (85.6 × 53.98 mm) [10]. PAR was computed as:

PAR=PPASDA (1)

where PPA denotes the number of foreground pixels within the segmented packaging region and SDA represents the pixel area equivalent of the standardized imaging frame.

2.3.2. Surface texture and material classification.

The antibiotic packaging dataset comprised two dominant material types with distinct optical and structural properties. Blister packs exhibited smooth surfaces and specular reflections due to rigid transparent polyvinyl chloride (PVC) layers, whereas strip packs showed diffuse, direction-independent reflections arising from opaque laminated aluminum materials. These physical characteristics influence entropy-based classification, as smooth surfaces tend to generate lower entropy values, while diffuse materials produce higher entropy due to random light scatter.

Images were converted to HSV color space, and the V-channel underwent histogram equalization. Grayscale histograms were generated, and the first three statistical moments (mean, variance, and skewness) were combined with PAR for clustering analysis [11,12]. Small artifacts were removed using a threshold of T=0.005×(nrows×ncols) Image entropy was calculated to quantify surface reflectivity using (Fig 2):

Fig 2. Schematic representation of reflected light behavior and entropy-based classification of pharmaceutical packaging materials.

Fig 2

H=−∑p(i)log2p(i) (2)

where p(i)represents the normalized frequency of grayscale intensity level i, and Hdenotes the scalar entropy value reflecting texture randomness and surface complexity. Variable definitions supporting reproducibility are summarized in Supplementary Table S1 in S1 File.

2.3.3. Optical character recognition (OCR) features.

Each image was processed using Tesseract OCR v5.3 [13] following adaptive thresholding. The OCR module extracted alphanumeric information from segmented packaging regions, with emphasis on batch codes and product identifiers. The following variables were computed:

  • Character Confidence Score (CCS): Aggregate OCR confidence assigned at the character level [23].

  • Word Confidence Score (WCS): Aggregate confidence across contiguous word segments, derived from CCS values [24,25].

  • Levenshtein Edit Distance (LED): String distance between extracted text and Thai FDA registry entries, with a binary match defined as LED = 0 [26,27].

  • Text-to-PPA Ratio (TPR): Proportion of OCR-identified text pixels relative to the primary packaging area.

All OCR-derived metrics were included in the composite feature vector for downstream analysis. Definitions, measurement units, and relevance to clustering and DEA modeling are provided in Supplementary Table S1 in S1 File, with additional mathematical details summarized in Supplementary Table S7 in S1 File.

2.4. Study population and sampling

Field surveys conducted in 2021 across four eastern provinces of Thailand identified 36 systemically used antibiotics registered between 2016 and 2020. One brand per active ingredient was selected using simple random sampling. Three units per brand were purchased from community drugstores, yielding a total of 108 physical packages. Full metadata for all sampled products are summarized in Supplementary Table S2 in S1 File.

2.5. External benchmark and integration

U.S. medicine-use data were obtained from the IQVIA Institute report [28]. Drug classes were mapped to Thai mechanistic groupings, and each physical package was assigned a unique study identifier linking image features, metadata, and market information within a relational database.

2.6. Statistical and efficiency analysis

2.6.1. Clustering analysis.

Unsupervised clustering was employed to explore latent structural patterns among antibiotic packages without assuming predefined class labels. K-means clustering was selected for its interpretability, computational efficiency, and suitability for continuous feature spaces derived from image and OCR metrics. All features were normalized using min–max scaling prior to clustering.

The optimal number of clusters was determined using the Calinski–Harabasz (CH) index:

CH=tr(Bk)/(k−1)tr(Wk)/(n−k) (3)

where tr(Bk) and tr(Wk) denote between- and within-cluster dispersion, respectively, k  = number of clusters, and n is the total number of samples [14–16]. The optimal solution (k=9) yielded the highest CH score and was used for subsequent analyses. Cluster characteristics and distributions are reported in Supplementary Tables S4 in S1 File and S6.

2.6.2. DEA efficiency modeling.

DEA was applied as an analytical evaluation layer rather than as a predictive classifier. Each antibiotic package was modeled as a decision-making unit (DMU) transforming multiple physical and OCR-derived inputs into identification-related outputs. DEA analysis employed the CCR model [29], formulated as (Fig 3):

Fig 3. Flowchart illustrating the combined machine-learning and DEA-based analytical framework for packaging evaluation.

Fig 3

maxu,v(uTy0vTx0),   subject to uTyjvTxj≤1,   ∀j;  u,v ≥0 (4)

where yjand xjrepresent output and input vectors for DMU j, respectively, and uand vare optimized weight vectors [30,31]. DEA efficiency scores (θ) were computed using Microsoft Excel Solver. DMUs with θ=1were classified as efficient, while those with θ<1were considered suboptimal. Full DEA results are provided in Supplementary Table S5 in S1 File.

2.7. Methodological Assumptions and Limitations

Several methodological considerations are acknowledged. The dataset reflects commonly used antibiotic products in Thailand and may not capture the full diversity of global packaging designs. Imaging was conducted under controlled laboratory conditions, which may differ from field-based acquisition environments. Additionally, OCR performance may be influenced by language, font variability, and print degradation not fully represented in the current sample. These assumptions provide context for interpretation of subsequent results.

3. Results

3.1. Clustering of physical and optical features

The optimal number of clusters was determined to be nine, based on the Calinski–Harabasz (CH) index (CH = 1532.6). This configuration offered the best balance of intra-cluster similarity and inter-cluster separation [7].

Cluster 1 was the largest group (n = 9), predominantly composed of blister packs with mid-range entropy (7.2–7.6) and moderate PAR values (1.2–1.45). In contrast, strip packs—which tend to exhibit diffuse reflectivity—were distributed across higher-entropy clusters (H > 7.8), demonstrating higher surface complexity.

Fig 4A illustrates the strong linear correlation between entropy and PAR across all samples (R² = 0.9072), confirming the underlying clustering mechanism. The left panel displays the entropy–PAR scatter plot used for initial grouping, while the middle panel summarizes the K-means clustering algorithm flow and image inputs. A total of nine clusters were established, each characterized by distinct combinations of PAR and entropy [8,32]. Fig 4B presents the Cluster summary, outlining the composition and statistical features for each group. These patterns align with the material classification established in Section 2.3.2.

Fig 4. Clustering analysis of pharmaceutical packaging features.

Fig 4

(A) Scatter plot of image entropy versus Packaging Area Ratio (PAR) showing the cluster assignments obtained from K-means clustering. Each color represents a different cluster. (B) Distribution of pharmaceutical packaging samples across the nine identified clusters. (C) Summary of the dominant packaging type and the number of products contained within each cluster.

  • Detailed definitions of feature variables (e.g., entropy, PAR, OCR scores) are provided in Supplementary S1 Table in S1 File.

  • Numerical cluster composition and descriptive statistics are summarized in Table 1.

  • Interpretation of these findings is further elaborated in Section 4: Discussion.

Table 1. Cluster Distribution and Key Statistics of Antibiotic Packages (n = 36).

Cluster No. of Packs Dominant Packaging Entropy (Mean ± SD) PAR (Mean ± SD) Notes
1 9 Blister 7.34 ± 0.11 1.33 ± 0.07 Smooth, high OCR accuracy
2 4 Strip 8.02 ± 0.14 1.12 ± 0.08 Irregular edge reflection
3 3 Blister 7.20 ± 0.09 1.47 ± 0.06 Mid-range entropy cluster
4 4 Blister 7.60 ± 0.13 1.39 ± 0.05 DEA-efficient cluster
5 3 Strip 8.20 ± 0.16 1.28 ± 0.09 High entropy group
6 3 Blister 7.41 ± 0.10 1.25 ± 0.07 Uniform OCR region
7 3 Strip 8.12 ± 0.12 1.30 ± 0.11 Higher OCR noise
8 4 Blister 7.38 ± 0.08 1.36 ± 0.06 DEA-optimal pack type
9 3 Strip 8.06 ± 0.17 1.15 ± 0.10 Irregular font/background

All nine clusters identified by the K-means clustering analysis are summarized in Fig 4, including their distribution and dominant packaging characteristics.

The figure presents the clustering results derived from image-based packaging descriptors and provides an overview of cluster composition without additional interpretive commentary.

3.2. Evaluation of OCR-derived features for API identification

3.2.1. Confidence metrics in OCR parsing.

Five feature sets—spanning image-based and OCR-derived metrics—were tested for their ability to correctly identify the active pharmaceutical ingredient (API). Among these, Character Confidence Score (CCS) and Word Confidence Score (WCS) achieved the highest predictive accuracy, exceeding 95% in most clusters. Strip-pack-dominated clusters showed lower OCR accuracy, underscoring the influence of surface irregularity [33,34].

A multivariate regression model showed standardized beta coefficients of β = 0.62 (WCS) and β = 0.57 (CCS), indicating strong predictive influence. In contrast, PAR and Text-to-PPA Ratio (TPR) had moderate contributions, while Levenshtein Edit Distance (LED) and text-region density were more significant in noisy OCR settings. These results validate the integration of OCR-based confidence metrics in automated drug package identification pipelines [35,36].

3.2.2 DEA-based efficiency analysis of packaging.

Each antibiotic pack was modeled as a Decision-Making Unit (DMU) within the Data Envelopment Analysis (DEA) framework. Input variables included entropy, PAR, histogram variance, and OCR confidence scores; the output was correct API identification. The efficiency threshold was set at DEA score = 1.00, indicating the most optimized input-output relationship under the model’s assumptions.

Efficiency scores ranged from 0.56 to 1.00, with Clusters 4 and 8 containing the highest number of DEA-efficient DMUs. These clusters also aligned with the most visually coherent and machine-readable packaging types, reinforcing the structural advantages of such designs for digital informatics systems [37,38].

3.2.3. Feature-level predictive power.

To strengthen interpretability, the individual contribution of each feature toward API recognition was evaluated using composite scoring and DEA regression weights. Confidence-based metrics (CCS and WCS) showed dominant influence in predicting correct API identification, consistent across cluster groups. Image-derived inputs such as entropy and PAR contributed indirectly via enhancing readability and structural integrity of the packaging. Cross-referencing these contributions with DEA outputs reveals their weighted impact, confirming the role of composite feature integration.

3.3. Packaging type trends and performance patterns

Blister packs demonstrated consistent mid-range entropy and high DEA efficiency, corroborating their smooth and specular surface features described in Section 2.3.2. Conversely, strip packs were associated with higher entropy variation and lower OCR reliability. This dichotomy was evident when plotting entropy versus PAR across pack types (Fig 6A), revealing material–structure interactions that affect image readability and OCR fidelity [36]. Fig 6B adds a feature-wise accuracy analysis, comparing five composite models across all clusters. OCR-based features—specifically WCS and CCS—were the most consistent performers across all cluster types. Additional radar chart data in Fig 7 supports this conclusion.

3.4. Feature Contribution Summary

Fig 7 summarizes the impact of each extracted feature—entropy, PAR, CCS, WCS, LED, and TPR—on API identification. Radar plots confirm that WCS and CCS are the dominant predictors, followed by LED. Image-derived metrics (PAR, entropy) contributed indirectly via structural readability and input weighting in the DEA model [38].

4. Discussion

4.1. Principal findings

This study demonstrates the feasibility of combining physical and optical features—specifically image entropy, Packaging Area Ratio (PAR), and OCR-derived confidence metrics—to cluster antibiotic packaging types and evaluate their relative efficiency for automated identification. Using unsupervised K-means clustering, nine distinct packaging groups were identified, with a strong correlation observed between entropy and PAR (R² = 0.9072), supporting their role as foundational descriptors of packaging structure.

DEA modeling further identified Clusters 4 and 8 as DEA-efficient, indicating favorable input–output alignment under comparable analytical conditions. OCR-based metrics, including Word Confidence Score (WCS) and Character Confidence Score (CCS), showed stronger associations with correct API identification than image-derived features alone, highlighting the value of text-based confidence information when integrated into a composite informatics framework. Fig 5 reinforces these findings by illustrating the role of DEA as an evaluation layer linking image- and OCR-derived inputs to identification outcomes, while Table 1 provides cluster-level statistical validation. Additional details on cluster composition, feature distributions, and packaging–API traceability are provided in Supplementary Tables S4–S6 in S1 File.

Fig 5. DEA-based evaluation of antibiotic packaging identification efficiency.

Fig 5

(A) Relationship between packaging area ratio (PAR), image entropy, and identification-related output signals, illustrating how physical packaging characteristics influence machine-readability. (B) Schematic representation of the DEA framework, where image-derived and OCR-based features are treated as inputs and identification performance as output, positioning DEA as an evaluation layer rather than a classifier. (C) Summary of DEA efficiency scores across packaging clusters under comparable analytical conditions. The figure illustrates how DEA can be used to benchmark packaging configurations based on image-derived and OCR-based characteristics.

4.2. Novelty and Technical Contribution

This work advances existing literature in several important ways. First, it introduces a hybrid feature space that integrates entropy-based texture measures, geometric area descriptors (PAR), and OCR confidence metrics, specifically tailored to the analysis of pharmaceutical packaging rather than pill-level imagery. Second, by embedding these features within a DEA-based efficiency framework, the study bridges computational image analysis with decision science, enabling structured benchmarking of packaging configurations without reliance on supervised classification models.

To our knowledge, this study is among the early works to provide a comprehensive feature-to-efficiency mapping (Fig 6) and a cross-validated composite feature emphasis summary (Fig 7) within a unified analytical framework. Compared with prior studies that primarily rely on shape- or color-based clustering [7,8], the proposed multi-feature integration supports broader generalisability and improved automation potential. Supplementary Table S7 in S1 File further clarifies the mathematical logic underlying the DEA variable construction, facilitating replication and adaptation of the framework to other packaging or labeling contexts.

Fig 6. Comparative variation of feature–output relationships across packaging configurations.

Fig 6

(A) Relative variation of DEA-related input and output measures across pharmaceutical products, illustrating sensitivity of feature configurations rather than performance evaluation. (B) Comparative trends of identification consistency across cluster groups and feature combinations. The figure is intended to illustrate behavioral variation and relative sensitivity of different feature sets, not to provide accuracy-based performance benchmarking.

Fig 7. Relative emphasis of feature categories in API identification.

Fig 7

Radar chart summarizing the relative emphasis of different feature categories (OCR confidence scores, entropy-based image features, packaging area ratio, and PPA-derived measurements) used within the proposed framework. The percentages represent descriptive, normalized summaries intended to illustrate relative feature emphasis rather than statistically learned importance or performance-based weighting.

4.3. Clinical and Informatics Implications

From a clinical informatics perspective, the findings highlight how packaging structure—particularly surface smoothness, reflectivity, and text clarity—can influence OCR reliability and, by extension, automated medication identification. Packaging clusters associated with higher DEA efficiency and stronger OCR confidence metrics may inform future considerations for machine-readable packaging design in digital dispensing environments. In community pharmacy or field-based settings where optical capture is commonly used, such insights may help improve robustness against variability in image acquisition and packaging heterogeneity.

These implications should be interpreted as analytical insights intended to inform packaging evaluation and design, rather than as direct clinical or regulatory decision-making recommendations. Nevertheless, the observed associations align with broader international efforts, including WHO and GS1 initiatives, aimed at improving digital readability and interoperability of pharmaceutical labeling [36,37]. Cross-cluster comparisons and DEA unit-level analyses supporting these interpretations are detailed in Supplementary Tables S5 and S6 in S1 File.

4.4. Limitations and Future Directions

Several limitations should be acknowledged. The sample size (n = 36) may not fully capture the diversity of antibiotic packaging encountered across global supply chains. While the analysis prioritized packaging-level physical and optical features, content-level variability—such as font styles, multilingual labeling, and foil texture heterogeneity—was not exhaustively examined. Future studies should expand the dataset to include a broader range of international packaging formats and explore the integration of deep learning approaches for automated segmentation and feature extraction.

Although DEA proved effective for efficiency evaluation in this context, future work may incorporate multi-objective optimization frameworks to balance digital readability with additional considerations such as packaging cost, environmental impact, and manufacturing constraints. Ensemble clustering techniques could also be explored to assess the stability of packaging groupings across datasets. Detailed methodological descriptions provided in the Supplementary Materials are intended to support future comparative benchmarking and extension of the proposed framework.

4.5. Reproducibility and Methodological Transparency for Implementation

The proposed framework emphasizes reproducibility, transparency, and interpretability to facilitate adoption and extension by other researchers. All variables, equations, and analytical parameters are fully defined in Section 2 and linked to corresponding Supplementary Tables. Figs 4–7 were designed to clarify feature derivation, clustering logic, and efficiency evaluation, while Table 1 summarizes cluster characteristics in a reader-accessible format without altering analytical outcomes.

The radar chart in Fig 7 provides a descriptive summary of relative feature emphasis within the framework and may support exploratory decision-making in packaging redesign contexts. Together with Supplementary Tables S1–S8 in S1 File and the detailed methodological descriptions provided in the Supplementary Appendix, these elements enable independent understanding and replication of the analytical workflow.

5. Conclusion

This study presents a composite informatics framework that integrates image-derived features and OCR-based confidence metrics to examine the packaging characteristics of 36 commonly used antibiotic products. The analysis indicates that image entropy and Packaging Area Ratio (PAR) are informative descriptors for exploratory clustering of packaging types, while OCR-based measures, including Word Confidence Score (WCS) and Character Confidence Score (CCS), are strongly associated with correct API identification within the proposed analytical framework. Using a combination of K-means clustering and Data Envelopment Analysis (DEA), nine distinct packaging clusters were identified, with Clusters 4 and 8 exhibiting comparatively favorable input–output efficiency profiles under the study’s assumptions [7,34,35].

By integrating physical packaging descriptors and OCR confidence metrics within a DEA-based evaluation layer, the proposed framework offers a replicable and mathematically grounded approach for assessing the digital readability of pharmaceutical packaging. The combined use of visual and textual feature sets supports more robust analytical characterization in environments where heterogeneous packaging designs complicate automated identification. Detailed methodological descriptions, supplementary analyses, and cluster-level summaries provided in Supplementary Tables S1–S8 in S1 File are intended to support transparency and independent replication of the analytical workflow [6,33,37,38].

Overall, the findings suggest that improved alignment between packaging design and machine-readable characteristics may enhance the reliability of digital drug identification systems. As an analytical and benchmarking tool, the proposed framework provides a structured basis for exploring packaging-level factors relevant to medication safety, digital health informatics, and pharmaceutical supply chain analysis, with potential applicability to broader contexts where visual and textual information must be jointly evaluated [39,27,8,36–38].

Supporting information

S1 File. Supplementary Methods, Supplementary Tables S1–S8, and Supplementary Note.

This file contains supplementary methods for image acquisition and preprocessing, feature extraction procedures, OCR metrics, DEA configuration, Supplementary Tables S1–S8, and supplementary interpretation of DEA results.

(DOCX)

pone.0354277.s001.docx (35.6KB, docx)
S2 Dataset. Minimal dataset underlying the findings of the study.

This dataset contains raw image-derived variables, OCR-derived variables, clustering assignments, DEA input/output variables, and the values used to generate the reported figures and descriptive statistics reported in the manuscript.

(ZIP)

pone.0354277.s002.zip (62.5KB, zip)

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

This work was supported by the National Research Council of Thailand (Award No. 5.2/2562; recipient: SM; website: https://www.nrct.go.th). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.World Health Organization. Global Action Plan on Antimicrobial Resistance. Geneva: WHO. 2015. [DOI] [PubMed] [Google Scholar]
  • 2.Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Ther Adv Drug Saf. 2014;5(6):229–41. doi: 10.1177/2042098614554919 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Holmes AH, Moore LSP, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016;387(10014):176–87. doi: 10.1016/S0140-6736(15)00473-0 [DOI] [PubMed] [Google Scholar]
  • 4.Okumura J, Wakai S, Umenai T. Drug utilisation and self-medication in rural communities in Vietnam. Soc Sci Med. 2002;54(12):1875–86. doi: 10.1016/s0277-9536(01)00155-1 [DOI] [PubMed] [Google Scholar]
  • 5.Kotwani A, Wattal C, Joshi PC, Holloway K. Irrational use of antibiotics and role of the pharmacist: an insight from a qualitative study in New Delhi, India. J Clin Pharm Ther. 2012;37(3):308–12. doi: 10.1111/j.1365-2710.2011.01293.x [DOI] [PubMed] [Google Scholar]
  • 6.Puspitasari HP, Faturrohmah A, Hermansyah A. Do Indonesian community pharmacy workers respond to antibiotics requests appropriately?. Trop Med Int Health. 2011;16(7):840–6. doi: 10.1111/j.1365-3156.2011.02782.x [DOI] [PubMed] [Google Scholar]
  • 7.Bijral RK, Manhas J, Sharma V. Characterization of molecular dynamic trajectory using k-means clustering. Rising threats in expert applications and solutions. Springer. 2022. [Google Scholar]
  • 8.Lai M-C, Huang H-C, Wang W-K. Designing a knowledge-based system for benchmarking: A DEA approach. Knowledge-Based Systems. 2011;24(5):662–71. doi: 10.1016/j.knosys.2011.02.006 [DOI] [Google Scholar]
  • 9.Smith R. An Overview of the Tesseract OCR Engine. In: Ninth International Conference on Document Analysis and Recognition (ICDAR 2007) Vol 2. 2007;629–33. doi: 10.1109/icdar.2007.4376991 [DOI] [Google Scholar]
  • 10.Sterkens W, Diaz-Romero DJ, Xiao B, Wu B, Goedemé T, Dewulf W, et al. Computer vision and optical character recognition for the classification of batteries from WEEE. Procedia CIRP. 2022;105:110–5. doi: 10.1016/j.procir.2022.02.019 [DOI] [Google Scholar]
  • 11.Yihong Xu, Nagy G. Prototype extraction and adaptive OCR. IEEE Trans Pattern Anal Machine Intell. 1999;21(12):1280–96. doi: 10.1109/34.817408 [DOI] [Google Scholar]
  • 12.Dengel A, Hoch R, Hönes F, Jäger T, Malburg M, Weigel A. TEchniques for improving ocr results. Handbook of Character Recognition and Document Image Analysis. World SCIENTIFIC. 1997. p. 227–58. doi: 10.1142/9789812830968_0008 [DOI] [Google Scholar]
  • 13.Sarkar P, Baird H, Henderson J. Triage of OCR results using ‘confidence’ scores. In: Document Recognition and Retrieval IX. 2002;50–8. doi: 10.1117/12.450747 [DOI] [Google Scholar]
  • 14.Gagolewski M, Bartoszuk M, Cena A. Are cluster validity measures (in)valid?. Inf Sci. 2021;581:620–36. doi: 10.1016/j.ins.2021.09.061 [DOI] [Google Scholar]
  • 15.Skelton M, Huysveld S, De Meester S, Van Geem KM, Dewulf J. Statistical entropy of resources using a categorization tree for material enumeration: Framework development and application to a plastic packaging case study. Resour Conserv Recycl. 2022;181:106259. doi: 10.1016/j.resconrec.2022.106259 [DOI] [Google Scholar]
  • 16.Mao Y, Li J, Liu Y. Evaluating Business Performance of China’s Pharmaceutical Companies Based on Data Envelopment Analysis. Studies on Ethno-Medicine. 2014;8(1):51–60. doi: 10.1080/09735070.2014.11886472 [DOI] [Google Scholar]
  • 17.Commission Internationale de l’Éclairage. Colorimetry—Part 4: CIE 1976 Lab* Colour Space. CIE. 2004. https://cie.co.at/publications/colorimetry-part-4-cie-1976-lab-colour-space-0 [Google Scholar]
  • 18.Wyszecki G, Stiles WS. Color Science: Concepts and Methods, Quantitative Data and Formulae. 2nd ed. Wiley. 2000. [Google Scholar]
  • 19.Berns RS. Billmeyer and Saltzman’s Principles of Color Technology. 3rd ed. Wiley-Interscience. 2000. [Google Scholar]
  • 20.Bochkovskiy A, Wang CY, Liao HYM. YOLOv4: Optimal Speed and Accuracy of Object Detection. arXiv preprint. 2020. doi: arXiv:2004.10934 [Google Scholar]
  • 21.Otsu N. A Threshold Selection Method from Gray-Level Histograms. IEEE Trans Syst, Man, Cybern. 1979;9(1):62–6. doi: 10.1109/tsmc.1979.4310076 [DOI] [Google Scholar]
  • 22.Gonzalez RC, Woods RE. Digital Image Processing. 4th ed. Pearson. 2018. [Google Scholar]
  • 23.Nguyen TTH, Jatowt A, Coustaty M, Doucet A. Survey of Post-OCR Processing Approaches. ACM Comput Surv. 2021;54(6):1–37. doi: 10.1145/3453476 [DOI] [Google Scholar]
  • 24.Song Q, Jiang Q, Zhang R, Wei X. Robust Lexicon-Free Confidence Prediction for Text Recognition. In: 2020 25th International Conference on Pattern Recognition (ICPR). 2021. 3232–9. doi: 10.1109/icpr48806.2021.9412671 [DOI] [Google Scholar]
  • 25.MIMS T. Find Drugs. https://www.mims.com/thailand/drug. 2021. Accessed 2020 October 24. [Google Scholar]
  • 26.American Pharmacists Association, Lexi-Comp I. Drug Information Handbook: A Clinically Relevant Resource for All Healthcare Professionals. 24 ed. Hudson, Ohio: Lexi-Comp. 2015. [Google Scholar]
  • 27.Bhargava A. Grouping of medicinal drugs used for similar symptoms by mining clusters from drug benefits reviews. In: Proceedings of the International Conference on Sustainable Computing in Science, Technology and Management (SUSCOM). 2019.
  • 28.IQVIA Institute. Medicine Use and Spending in the U.S. A Review of 2019 and Outlook to 2024. Parsippany, NJ: IQVIA. 2020. [Google Scholar]
  • 29.Charnes A, Cooper WW, Rhodes E. Measuring the efficiency of decision-making units. Eur J Oper Res. 1978;2(6):429–44. doi: 10.1016/0377-2217(78)90138-8 [DOI] [Google Scholar]
  • 30.Jung S, Son J, Kim C, Chung K. Efficiency Measurement Using Data Envelopment Analysis (DEA) in Public Healthcare: Research Trends from 2017 to 2022. Processes. 2023;11(3):811. doi: 10.3390/pr11030811 [DOI] [Google Scholar]
  • 31.Ting H-W, Chung S-L, Chen C-F, Chiu H-Y, Hsieh Y-W. A drug identification model developed using deep learning technologies: experience of a medical center in Taiwan. BMC Health Serv Res. 2020;20(1):312. doi: 10.1186/s12913-020-05166-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Shiau WL, Wang X, Zheng F. What are the trend and core knowledge of information security? A citation and co-citation analysis. Inf Manag. 2023;60(3):103774. doi: 10.1016/j.im.2022.103774 [DOI] [Google Scholar]
  • 33.Raza MA, Aziz S, Noreen M, Saeed A, Anjum I, Ahmed M, et al. Artificial Intelligence (AI) in Pharmacy: An Overview of Innovations. Innov Pharm. 2022;13(2):10.24926/iip.v13i2.4839. doi: 10.24926/iip.v13i2.4839 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Roehrig H, Rehm K, Silverstein LD, Dallas WJ, Fan J, Krupinski EA. Color calibration and color-managed medical displays: does the calibration method matter?. In: Medical Imaging 2010: Image Perception, Observer Performance, and Technology Assessment, 2010.
  • 35.Gao Y, Cheng Y, Zhang H, Zou N. Dynamic illuminance measurement and control used for smart lighting with LED. Measurement. 2019;139:380–6. doi: 10.1016/j.measurement.2019.03.003 [DOI] [Google Scholar]
  • 36.Cleophas TJ, Zwinderman AH. Composite feature effects in AI models for medication safety. Machine Learning in Medicine – Practical Applications. Springer. 2022. p. 123–37. [Google Scholar]
  • 37.Lee Y-B, Park U, Jain AK, Lee S-W. Pill-ID: Matching and retrieval of drug pill images. Pattern Recognition Letters. 2012;33(7):904–10. doi: 10.1016/j.patrec.2011.08.022 [DOI] [Google Scholar]
  • 38.Liang Z, Zhou L, Liu X, Wang X. Image tracking for the high similarity drug tablets based on light intensity reflective energy and artificial neural network. Comput Math Methods Med. 2014;2014:304685. doi: 10.1155/2014/304685 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Saengcharoen W, Lerkiatbundit S. Practice and attitudes regarding the use of antibiotics among Thai community pharmacists. Southeast Asian J Trop Med Public Health. 2010;41(2):426.20578527 [Google Scholar]

Decision Letter 0

Renier Mendoza

17 Sep 2025

-->PONE-D-25-36293-->-->Image-Based Identification and Optimization Modeling of Antibiotic Packaging Using Unsupervised Learning Techniques-->-->PLOS ONE

Dear Dr. Muongmee,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The manuscript presents a relevant study on applying image processing, OCR, and machine learning to analyze antibiotic packaging in Thailand, with potential contributions to medication safety. However, several areas need further development. The methodology requires clearer descriptions of algorithms, models, and equations, along with appropriate validation to support the reported results. Improvements in writing, formatting, figures, and citations would also strengthen readability. Providing access to data or code, comparing results more critically with related studies, and outlining future directions would enhance the paper’s clarity, rigor, and overall impact. Please refer to the reviewers' comments below for the complete recommendations.-->-->

Please submit your revised manuscript by Nov 01 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:-->

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Renier Mendoza

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information.

3. Please note that PLOS One has specific guidelines on code sharing for submissions in which author-generated code underpins the findings in the manuscript. In these cases, we expect all author-generated code to be made available without restrictions upon publication of the work. Please review our guidelines at https://journals.plos.org/plosone/s/materials-and-software-sharing#loc-sharing-code and ensure that your code is shared in a way that follows best practice and facilitates reproducibility and reuse.

4. We note that your Data Availability Statement is currently as follows: [All relevant data are within the manuscript and its Supporting Information files.]

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories.

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

5. When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process.

6. Please upload a new copy of Figures, 1, 2, 4, 5, 6, 7, 8, and 9 as the details are not clear. Please follow the link for more information: https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/

If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

-->Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. -->

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: Partly

**********

-->2. Has the statistical analysis been performed appropriately and rigorously? -->

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: N/A

**********

-->3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #1: No

Reviewer #2: No

Reviewer #3: Yes

**********

-->4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

-->5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #1: The manuscript explores the application of image processing, optical character recognition (OCR), and unsupervised learning techniques to analyze the packaging of antibiotic products distributed in Thailand. The study’s stated goal is to develop a method for improving medication safety through automated analysis of packaging characteristics using clustering (via K-means) and efficiency assessment (via Data Envelopment Analysis, DEA).

While the topic is relevant and potentially impactful in pharmacy automation and drug safety, the manuscript suffers from several critical shortcomings in methodology, clarity of writing, statistical rigor, and presentation. At its current stage, the paper does not meet the standards for publication in PLOS ONE.

1. Writing Quality and Presentation

The manuscript requires substantial improvements in writing and formatting:

There are multiple typographical errors, such as:

"traceabilit" instead of "traceability" (page 1)

"recognizability" instead of "recognizability" (page 5)

"k-mean" instead of "k-means" in graph labels

There are numerous formatting inconsistencies, including sudden changes in font style and size, making the manuscript visually disjointed and difficult to follow.

The writing is often verbose and repetitive, particularly in the introduction and methods sections. Key methodological steps are not always clearly delineated or logically presented.

Terminology such as "identification" is overused and incorrectly applied to unsupervised methods. The paper should clearly distinguish between clustering, classification, and detection.

2. Reproducibility and Transparency

There is no publicly accessible code, workflow diagram, or supplementary material that would enable replication of the methods.

The authors state that the data are available, but there are no links or repositories provided.

3. Scientific Soundness and Methodological Issues

The methodology section is underdeveloped and lacks sufficient clarity. Many technical terms are introduced without adequate explanation or justification (e.g., entropy smoothing, histogram stretching, feature vector composition).

The paper heavily relies on unsupervised clustering (K-means) but makes repeated claims about classification accuracy, which is misleading. Clustering is not equivalent to classification, and the manuscript seemingly combines these concepts. This terminological confusion undermines the validity of reported performance claims (e.g., "accuracy > 95%" from unsupervised models without labeled data or classification evaluation metrics).

There is no use of supervised machine learning models (e.g., Random Forests, SVM, CNN) that would be standard for a classification task involving labeled packaging data. This weakens the empirical support for the claimed performance.

The DEA model is described mathematically, but it lacks interpretability and practical context. Its integration into the analysis is unclear.

4. Statistical and Validation Weaknesses

There is no cross-validation or external validation, which raises serious concerns about overfitting and generalizability, especially considering the small dataset of 36 antibiotic products.

Regression models with very low explanatory power (e.g., R² = 0.12) are still interpreted for insight, which is statistically inappropriate.

No confusion matrices, F1 scores, precision/recall, or other standard classification metrics are presented.

Overall Assessment

Despite the relevance of the topic and the potential utility of integrating image processing and OCR in pharmacy systems, this manuscript does not meet the technical and editorial standards required for publication. Major revisions would be needed to:

Clearly distinguish between clustering and classification,

Strengthen the methodology with supervised models and validation,

Improve statistical rigor,

Correct typographical and formatting issues,

Sharpen the clarity and coherence of the writing.

At this time, however, the manuscript may require more substantial revision than can typically be accommodated through peer review. For this reason, I recommend that the authors consider revising the manuscript thoroughly before resubmitting. I hope this feedback will be helpful in strengthening the paper.

Reviewer #2: - Best efforts were made in data acquisition.

- In Section 2.1 Step 3, specify the machine learning algorithms used.

- In Section 2.2 item #1, what was the pre-trained object detection model used? Please elaborate more on this.

- Please give more details/description about the Canny edge filter and Global Otsu thresholding and provide proper citations

- In Section 2.3, specify the distance metrics tested.

- Explain and describe Equation 1 — what is H? p(i)? What is the index of summation and the lower and upper limit of summation?

- In the last paragraph of Section 2.3, why did you choose F-score as your predictive performance? Moreover, is the 11% improvement in F-score from your results, or from reference [28]?

- In Table 1, how much does each feature affect the classification accuracy?

- Give proper citation to Tesseract OCR

- Properly cite Thai FDA registry;

- Properly cite DEA by Charnes et al.

- Fix equation (3) and its constraints

- Maximize E_0 with respect to what?

- The first constraint must be less than or equal to what?

- Second constraint: w_j, v_i >= 0

- Cite your reference for equation 3.

- There is room for improvement for the figures.

- Where can we access the data used in the study?

Minor comments:

1. Correct misspelled words in text and in images.

2. Please use high resolution figures and fix the font size.

3. Some section titles can be improved.

Reviewer #3: The introduction repeats well-known facts about antibiotic misuse without tightly linking them to the image-analysis focus.

International comparisons (e.g., U.S. data) are mentioned but not integrated meaningfully with the Thai dataset.

The methods section is very detailed about imaging conditions (lux, color calibration, equipment), but some parts feel excessive and could overwhelm readers while still leaving gaps (e.g., no explanation of why only 36 antibiotics were selected).

The description of pre-processing and clustering lacks validation: there is no mention of cross-validation, external test sets, or reproducibility checks.

The results are overloaded with regression equations (R² values reported even when correlations are weak, e.g., R² = 0.12) without critical interpretation.

The discussion mostly restates results instead of critically comparing them with related studies.

No future work or roadmap is clearly outlined in the conclusion section.

**********

-->6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy.-->

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2026 Jul 27;21(7):e0354277. doi: 10.1371/journal.pone.0354277.r002

Author response to Decision Letter 1


4 Oct 2025

Response to Reviewers

We would like to sincerely thank the Academic Editor and the Reviewers for their thoughtful and constructive comments. We have carefully revised the manuscript in response to these suggestions.

Below, we provide a point-by-point rebuttal letter. Reviewer comments are presented in italics, followed by our detailed responses and the corresponding locations in the revised manuscript.

For clarity, we also include the Reviewer Comment-to-Revision Mapping Table (Full Coverage) (see attached document), which summarizes all comments, manuscript locations, and revisions implemented.

We hope these revisions adequately address all reviewer concerns. We are deeply grateful for the constructive feedback, which has substantially improved the clarity, rigor, and overall quality of the manuscript.

Attachment

Submitted filename: Response to Reviewers.pdf

pone.0354277.s004.pdf (109.5KB, pdf)

Decision Letter 1

Renier Mendoza

7 Oct 2025

-->PONE-D-25-36293R1-->-->Image-Based Identification and DEA-Based Optimization Modeling of Antibiotic Packaging Using Unsupervised Learning Techniques-->-->PLOS ONE

Dear Dr. Muongmee,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please refer to my comments/suggestions below.

Please submit your revised manuscript by Nov 21 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:-->

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Renier Mendoza

Academic Editor

PLOS ONE

Journal Requirements:

If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Additional Editor Comments:

Please resubmit your manuscript together with a detailed, per-reviewer response addressing each comment and recommendation from the referees. The current Reviewer’s Comment-to-Revision Mapping Table is difficult to follow. You may still include it, but kindly provide a separate file that clearly presents your point-by-point responses organized by reviewer.

[Note: HTML markup is below. Please do not edit.]

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2026 Jul 27;21(7):e0354277. doi: 10.1371/journal.pone.0354277.r004

Author response to Decision Letter 2


21 Oct 2025

Rebuttal Letter to the Academic Editor and Reviewers

Manuscript ID: PONE-D-25-36293R1

Title: Image-Based Identification and DEA-Based Optimization Modeling of Antibiotic Packaging Using Unsupervised Learning Techniques

Cover Note

Dear Dr. Renier Mendoza and Esteemed Reviewers,

We sincerely thank the Academic Editor and the Reviewers for their thoughtful and constructive feedback. We have carefully revised the manuscript to address every comment in detail. The manuscript has been substantially improved in clarity, methodological rigor, and contextual interpretation.

We believe these revisions fully address all reviewer concerns and align the paper with PLOS ONE publication standards.

Thank you for your time and consideration.

Sincerely,

Ms. Suthabordee Muongmee

Corresponding Author

Faculty of Pharmaceutical Science, Burapha University

Email: suthabordee@go.buu.ac.th

Attachment

Submitted filename: Rebuttal_Letter_221025.pdf

pone.0354277.s005.pdf (80.5KB, pdf)

Decision Letter 2

Renier Mendoza

19 Dec 2025

-->PONE-D-25-36293R2-->-->Image-Based Identification and DEA-Based Optimization Modeling of Antibiotic Packaging Using Unsupervised Learning Techniques-->-->PLOS One

Dear Dr. Muongmee,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.-->-->

Please submit your revised manuscript by Feb 02 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:-->

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Renier Mendoza

Academic Editor

PLOS One

Journal Requirements:

1. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Additional Editor Comments:

A reviewer notes that only a few comments were addressed and that the manuscript requires substantial revision, particularly in rewriting the introduction to clearly motivate the study, situate it within existing literature, and explicitly state its novelty. Major issues remain with coherence, methodology clarity, placement of limitations and implications, correctness of references, and the quality and accuracy of figures, captions, and results discussion.

[Note: HTML markup is below. Please do not edit.]

Reviewer's Responses to Questions

-->Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.-->

Reviewer #3: (No Response)

Reviewer #4: (No Response)

**********

-->2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. -->

Reviewer #3: (No Response)

Reviewer #4: Partly

**********

-->3. Has the statistical analysis been performed appropriately and rigorously? -->

Reviewer #3: (No Response)

Reviewer #4: I Don't Know

**********

-->4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #3: (No Response)

Reviewer #4: Yes

**********

-->5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #3: (No Response)

Reviewer #4: No

**********

-->6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #3: (No Response)

Reviewer #4: Only a few of the reviewers’ comments have been addressed by the authors.

1. The introduction needs to be rewritten.

- The authors should clearly state the significance and background of the study. Why is automated dispensing needed now? Why focus on antibiotic packaging? Using terms like urgent and critical does not sufficiently motivate the study’s aims.

- The related literature on image-based identification methods and the use of AI in pharmaceuticals is insufficient. Although references are provided, the authors should briefly discuss the findings of those studies.

- The novelty of the study is not highlighted in the introduction; it should not be placed in the results discussion. Is the novelty in the method itself, or in its application to antibiotic packaging?

2. There is no coherent flow of discussion between sections or within the sections.

3. The methodology section requires major revision.

- Consider adding a figure showing the overall workflow or algorithm at the beginning of the section. This will help readers follow the subsections more easily.

- The discussion on PAR should be detailed in Subsection 2.3.1 rather than in the results section.

- K-means clustering is mentioned but not explained; only the analysis is provided.

- The novelty of the DEA approach is not emphasized, and the discussion of DEA remains unclear and lacking in detail.

- Overall, the authors should introduce technical terms with sufficient context and explain the purpose of each algorithm before presenting it.

4. The study’s limitations should appear before Section 3.

5. The discussion of forward-looking implications belongs in the introduction.

6. Incorrect references were provided in response #8.

7. Figure captions have improved but still lack clarity. The discussion of results also needs improvement. It may be better to move the tables in the supplementary materials to the main text, as they are easier to understand than the figures in Section 3.

8. Figure 5 contains typographical errors.

9. Regarding comment #22, it is better to use the original figures and discuss each one.

**********

-->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy.-->

Reviewer #3: No

Reviewer #4: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

PLoS One. 2026 Jul 27;21(7):e0354277. doi: 10.1371/journal.pone.0354277.r006

Author response to Decision Letter 3


31 Dec 2025

Manuscript ID: PONE-D-25-36293R2

Manuscript Title: Image-Based Identification and DEA-Based Optimization Modeling of

Antibiotic Packaging Using Unsupervised Learning Techniques

Journal: PLOS ONE

Dear Academic Editor,

We sincerely thank you and the reviewers for the careful evaluation of our manuscript and

for the constructive feedback provided. In response, we have undertaken a substantial

revision of the manuscript to address all comments raised, with particular attention to

conceptual clarity, methodological coherence, and alignment with PLOS ONE editorial

expectations.

Summary of Major Revisions

1. The Introduction was fully rewritten using a problem-driven framing to clearly motivate

the need for packaging-level antibiotic identification within automated pharmacy and

dispensing workflows, with explicit articulation of study novelty.

2. The Methods section was reorganized to clarify the purpose of each analytical component

before technical implementation, improving coherence and interpretability.

3. Packaging Area Ratio (PAR) was reframed as a normalization and design-relevant metric

and relocated from the Results section to the Methods section, in accordance with reviewer

guidance.

4. The role of K-means clustering was clarified as exploratory and unsupervised, with

cluster descriptions explicitly presented as post-hoc interpretations. Data Envelopment

Analysis (DEA) was reframed as a decision-oriented evaluation and benchmarking layer

rather than a classifier.

5. Methodological assumptions and study limitations were relocated to appear before the

Results section, as explicitly requested by the reviewer.

6. Figures and captions were revised to improve clarity and prevent overinterpretation. In

particular, figures were refined to clearly distinguish exploratory analysis, efficiency

evaluation, and descriptive feature emphasis, and typographical errors were corrected.

A detailed, point-by-point response to all reviewer comments, including the exact location

of each revision in the manuscript, is provided in the accompanying Response to Reviewers

document. All changes are also visible in the revised manuscript with tracked changes.

We believe that these revisions fully address the reviewers’ concerns and substantially

strengthen the manuscript. We appreciate the opportunity to revise our work and

respectfully submit the revised manuscript for your reconsideration.

Sincerely,

Phakdee Sukpornsawan

First Author

Suthabordee Muongmee

Corresponding Author

Attachment

Submitted filename: Response to Reviewers R2.docx

pone.0354277.s006.docx (19.6KB, docx)

Decision Letter 3

Renier Mendoza

22 Jan 2026

-->PONE-D-25-36293R3-->-->Image-Based Identification and DEA-Based Optimization Modeling of Antibiotic Packaging Using Unsupervised Learning Techniques-->-->PLOS One

Dear Dr. Muongmee,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Kindly refer to the attached reviewer comments. Please revise the manuscript accordingly before it can be accepted for publication.-->-->

Please submit your revised manuscript by Mar 08 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:-->

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

-->If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Renier Mendoza

Academic Editor

PLOS One

Journal Requirements:

If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

-->Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.-->

Reviewer #4: (No Response)

**********

-->2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. -->

Reviewer #4: Partly

**********

-->3. Has the statistical analysis been performed appropriately and rigorously? -->

Reviewer #4: N/A

**********

-->4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #4: Yes

**********

-->5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #4: No

**********

-->6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #4: (No Response)

**********

-->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy.-->

Reviewer #4: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

-->

Attachment

Submitted filename: PLOS ONE review_.pdf

pone.0354277.s007.pdf (883.5KB, pdf)
PLoS One. 2026 Jul 27;21(7):e0354277. doi: 10.1371/journal.pone.0354277.r008

Author response to Decision Letter 4


29 Jan 2026

Dear Dr. Mendoza,

Thank you very much for your continued time and careful consideration of our manuscript. We are sincerely grateful for your additional editorial guidance, which has been instrumental in ensuring that the manuscript fully aligns with the scope, standards, and publication criteria of PLOS ONE.

In response to your editorial guidance, we have made the following final clarifications to the manuscript:

1. Scope and intended use of the framework

We have further clarified that the proposed approach is intended as an analytical and benchmarking framework for evaluating packaging-level machine-readability, rather than as a deployable clinical or regulatory decision-support system. This clarification has been incorporated into the Discussion and Conclusion sections to prevent any potential overinterpretation of the study’s scope or claims.

2. Reproducibility and transparency

To reinforce PLOS ONE’s reproducibility standards, we have added an explicit statement confirming that all algorithms, variables, feature definitions, and analytical steps are fully described in the Methods section and Supplementary Materials. This ensures that the analytical workflow can be independently understood and reproduced by readers without reliance on proprietary or undisclosed resources.

3. Clarification of figure interpretation

We have carefully reviewed all figures and their captions to ensure that they are consistently framed as exploratory, descriptive, or evaluative in nature, rather than as performance- or accuracy-benchmarking results. The revised captions and corresponding text now more clearly articulate the intended interpretive role of each figure and maintain a clear distinction between the Results and Discussion sections.

All substantive comments raised by the reviewers in the previous round have been fully addressed in the revised manuscript. The present revision therefore focuses exclusively on editorial-level clarification and alignment with journal policy, without introducing new analyses or extending the original claims.

We sincerely appreciate your guidance throughout the review process and thank you again for the opportunity to revise the manuscript accordingly. We hope that the manuscript in its current form will now be suitable for further consideration for publication in PLOS ONE.

Kind regards,

Suthabordee Muongmee, Ph.D.

Corresponding Author

Faculty of Pharmaceutical Sciences, Burapha University, Thailand

Email: suthabordee@go.buu.ac.th

ORCID: https://orcid.org/0000-0003-4033-3371

Attachment

Submitted filename: Response to Reviewers (Detailed Point-by-Point).pdf

pone.0354277.s008.pdf (85.1KB, pdf)

Decision Letter 4

Renier Mendoza

5 Feb 2026

-->PONE-D-25-36293R4-->-->Image-Based Identification and DEA-Based Optimization Modeling of Antibiotic Packaging Using Unsupervised Learning Techniques-->-->PLOS One

Dear Dr. Muongmee,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Mar 22 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:-->

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

-->If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Renier Mendoza

Academic Editor

PLOS One

Journal Requirements:

1. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

The reviewer notes that while the manuscript’s writing has improved, many revisions appear aimed at addressing reviewer comments rather than improving clarity for readers, resulting in confusing presentation and sections that read like rebuttal text rather than a cohesive paper. Although the study is considered interesting and potentially valuable, it contains numerous issues—including unclear explanations, missing definitions, inconsistent terminology, typographical errors, figure and table problems, and misplaced or redundant content—that need substantial correction. Please refer to the attached file for the detailed review.

[Note: HTML markup is below. Please do not edit.]

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

-->

PLoS One. 2026 Jul 27;21(7):e0354277. doi: 10.1371/journal.pone.0354277.r010

Author response to Decision Letter 5


7 Feb 2026

Dear Academic Editor and Reviewers,

We sincerely thank the Academic Editor and reviewers for their careful evaluation of our manuscript and for the constructive comments provided. We appreciate the opportunity to revise our work and have undertaken a comprehensive revision to address the concerns raised.

In this revision (R4), our primary objective was to improve clarity, narrative coherence, and reader accessibility, in line with the Academic Editor’s observation that portions of the previous revision appeared rebuttal-driven rather than manuscript-centered. Importantly, no new data, experiments, or analytical outcomes were added. All revisions focus on restructuring, clarification, and alignment of presentation with PLOS ONE’s editorial expectations.

Below, we summarize how the major concerns were addressed.

1. Overall clarity and manuscript coherence

Comment: The manuscript shows improvement in writing but remains confusing in places, with sections reading like rebuttal text rather than a cohesive paper.

Response: The manuscript was restructured to ensure a reader-first narrative throughout. The Introduction was rewritten to align reader expectations with the analytical scope and aims of the study (Section 1). The Methods, Results, Discussion, and Conclusion sections were revised to clearly separate descriptive reporting from interpretation and to eliminate rebuttal-style phrasing. Each section now serves a distinct and non-overlapping role, resulting in a continuous and cohesive narrative intended for readers unfamiliar with the prior review history.

2. Methods presentation and role clarification

Comment: Explanations in the Methods section were unclear, with missing definitions and blurred methodological roles.

Response: The Methods section was rewritten for clarity and explicit role separation (Section 2). The sequential analytical logic of the study is now clearly described, and the function of each analytical component is delineated. In particular, Data Envelopment Analysis (DEA) is explicitly framed as a comparative evaluation layer rather than a predictive or classification model (Section 2.6.2). Definitions of key variables and metrics were standardized and streamlined, with detailed mathematical descriptions retained in the Supplementary Materials to preserve reproducibility while improving readability.

3. Terminology consistency and definitions

Comment: Inconsistent terminology and missing definitions reduced clarity.

Response: Terminology was standardized across the manuscript. Key concepts, metrics, and analytical components are now defined once and used consistently throughout all sections. Redundant or ambiguous terms were removed to reduce reader confusion.

4. Figures and tables

Comment: Several figures and tables were unclear, redundant, or misplaced, with captions that did not adequately support standalone interpretation.

Response: All figures and tables were systematically reviewed and revised (Figures 1–7, Table 1). Each figure was assigned a single narrative role—methods illustration, results visualization, or discussion synthesis—and captions were rewritten to be fully self-contained. Interpretive or performance-based language was removed from captions, and figure placement was adjusted to align with the revised manuscript structure.

5. Results reporting versus interpretation

Comment: Results and interpretation were intermingled, and some sections read as justificatory.

Response: The Results section was rewritten to present observed patterns and quantitative outcomes only, without interpretation or explanatory language. All interpretive discussion has been relocated to the Discussion section, ensuring a clear separation between reporting and interpretation.

6. Discussion tone and scope

Comment: The Discussion contained defensive language and overlapping content.

Response: The Discussion was rewritten to focus on balanced interpretation of the findings without justification of methodological choices or overstatement of impact (Section 4). Interpretations are now explicitly contextualized within the analytical scope of the study, and limitations are acknowledged in a neutral and transparent manner.

7. Conclusion and Abstract alignment

Comment: The manuscript would benefit from clearer synthesis and alignment across sections.

Response: The Conclusion was rewritten to provide a concise synthesis of the study’s analytical contribution without repeating results or extending claims beyond the study scope. The Abstract was carefully reviewed and retained without substantive modification, as it already accurately reflected the revised manuscript and maintained a descriptive, non-promotional tone consistent with PLOS ONE guidelines.

We believe these revisions improve the clarity and coherence of the manuscript and align it more closely with PLOS ONE’s editorial expectations, while preserving the integrity of the original study. We are grateful for the insightful feedback provided and appreciate the opportunity to revise our work.

Thank you for your time and consideration.

Sincerely,

Suthabordee Muongmee, Ph.D

Attachment

Submitted filename: Response_R4_map to_Track_Changes.docx

pone.0354277.s009.docx (17.4KB, docx)

Decision Letter 5

Renier Mendoza

6 Apr 2026

-->PONE-D-25-36293R5-->-->Image-Based Identification and DEA-Based Optimization Modeling of Antibiotic Packaging Using Unsupervised Learning Techniques-->-->PLOS One

Dear Dr. Muongmee,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.-->--> -->-->The manuscript has improved in writing quality and presents interesting results, but its revisions appear focused on addressing reviewer comments rather than improving clarity, resulting in a presentation that is often confusing, inconsistent, and assumes too much prior knowledge. Numerous issues remain, including unclear explanations, missing definitions, typographical errors, and poorly presented figures and sections, indicating that substantial revisions are still needed for readability and coherence. Please refer to the attached file.

Please submit your revised manuscript by May 21 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:-->

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

-->

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only  the individual author can complete the verification step; PLOS staff cannot  verify ORCID iDs on behalf of authors.

We look forward to receiving your revised manuscript.

Kind regards,

Renier Mendoza

Academic Editor

PLOS One

Journal Requirements:

1. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

-->Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.-->

Reviewer #4: (No Response)

**********

-->2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. -->

Reviewer #4: Partly

**********

-->3. Has the statistical analysis been performed appropriately and rigorously? -->

Reviewer #4: No

**********

-->4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #4: Yes

**********

-->5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #4: Yes

**********

-->6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #4: The manuscript’s readability has improved significantly. However, not all of the reviewer comments have been fully addressed (see red comments). In some cases, the authors appear to have removed portions of the methodological discussion rather than providing further clarification, which limits the transparency of the approach.

Additionally, reproducibility remains a concern, as the figures have not been revised to enhance clarity and understanding. The presence of typographical errors in the figures is also distracting and should be carefully corrected.

**********

-->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy.-->

Reviewer #4: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

-->

Attachment

Submitted filename: PLOS ONE review__.pdf

pone.0354277.s010.pdf (887.2KB, pdf)
PLoS One. 2026 Jul 27;21(7):e0354277. doi: 10.1371/journal.pone.0354277.r012

Author response to Decision Letter 6


11 Apr 2026

We thank the Academic Editor and Reviewer #4 for their constructive comments. We have revised the manuscript accordingly to improve clarity, consistency, readability, figure presentation, and methodological transparency.

A detailed point-by-point response is provided in the separate “Response to Reviewers” file. Revised versions of the manuscript with and without track changes have also been uploaded.

We hope the revised manuscript is now suitable for further consideration.

Attachment

Submitted filename: Response to Reviewers (PLOS ONE)_2026.pdf

pone.0354277.s011.pdf (143.2KB, pdf)

Decision Letter 6

Renier Mendoza

19 Jun 2026

-->PONE-D-25-36293R6-->-->Image-Based Identification and DEA-Based Optimization Modeling of Antibiotic Packaging Using Unsupervised Learning Techniques-->-->PLOS One

Dear Dr. Muongmee,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.-->-->

Please submit your revised manuscript by Aug 03 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

-->

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

-->

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only  the individual author can complete the verification step; PLOS staff cannot  verify ORCID iDs on behalf of authors.

We look forward to receiving your revised manuscript.

Kind regards,

Renier Mendoza

Academic Editor

PLOS One

Journal Requirements:

1. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

Kindly address the reviewer's remaining minor comments before the paper can be recommended for publication.

[Note: HTML markup is below. Please do not edit.]

Reviewer's Responses to Questions

-->Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.-->

Reviewer #4: (No Response)

**********

-->2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. -->

Reviewer #4: Yes

**********

-->3. Has the statistical analysis been performed appropriately and rigorously? -->

Reviewer #4: N/A

**********

-->4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #4: Yes

**********

-->5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #4: Yes

**********

-->6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #4: I am still checking the same comments I raised in Revision 3 of the manuscript. Almost all of the comments have been addressed, but Figures 4 and 5 still contain inconsistencies that the authors should address. Otherwise, reproducibility remains an issue that needs to be resolved.

30. Figure 4B lacks a summary for Cluster 8. Additionally, there is no discussion/comments in the main text that talks about why there is NO Cluster 8 in their results. The authors said that they have addressed this but they still give the same figure as the one in Revision 3. NOT OK

31. Figure 4A uses different colors for clusters but does not include a legend identifying them. In particular, why are there blue, yellow, and green points in that plot. NOT OK

32. Figures 4 STILL contains unnecessary commentary since they still have the same Figure 4. NOT OK

33. Figure 5C and the new DEA efficiency summary does not match, e.g., Orcaptir has 0.93 score in the new figure but 0.96 in the old figure. No explanation for this in the rebuttal letter. Also, Cluster 2 – Orcaptrir Strip has 1.0 score but in the next table it is in Cluster 3 with score 0.93. The discussion said that efficiency scores ranged from 0.56 to 1.0 but it is not reflected in the figure. The caption for Figure 5C is Summary of DEA efficiency scores across representative packaging clusters and so, I do not know why there are no Clusters 5-9 and why is Cluster 4 repeated. Also, why the title DEA efficiency summary is repeated in the column and it is again repeated in the bottom of the figure.

**********

-->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy.-->

Reviewer #4: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

-->

Attachment

Submitted filename: PLOS ONE review_6.pdf

pone.0354277.s012.pdf (1.4MB, pdf)
PLoS One. 2026 Jul 27;21(7):e0354277. doi: 10.1371/journal.pone.0354277.r014

Author response to Decision Letter 7


26 Jun 2026

Dear Editor,

Thank you for your message. We have addressed the requested issues to allow the manuscript to proceed through the technical check.

First, we have uploaded a point-by-point Response to Reviewers document addressing all comments raised during this revision round. The manuscript has been revised accordingly, and all changes are shown in the marked-up manuscript file.

Second, we confirm that the submission contains the minimal data set underlying the findings of the study as Supporting Information. The dataset includes the raw values behind the reported descriptive statistics, the values used to generate graphs, extracted image-derived variables, annotated OCR results, clustering variables and assignments, and DEA input/output data required to reproduce the reported findings in their entirety. The Data Availability Statement has also been revised accordingly.

We hope that the revised submission now meets the technical requirements and can be forwarded for editorial consideration.

Sincerely,

Suthabordee Muongmee

Attachment

Submitted filename: Response to Reviewer_R6.docx

pone.0354277.s013.docx (14.5KB, docx)

Decision Letter 7

Renier Mendoza

6 Jul 2026

Image-Based Identification and DEA-Based Optimization Modeling of Antibiotic Packaging Using Unsupervised Learning Techniques

PONE-D-25-36293R7

Dear Dr. Muongmee,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Renier Mendoza

Academic Editor

PLOS One

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Renier Mendoza

PONE-D-25-36293R7

PLOS One

Dear Dr. Muongmee,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Renier Mendoza

Academic Editor

PLOS One

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Supplementary Methods, Supplementary Tables S1–S8, and Supplementary Note.

    This file contains supplementary methods for image acquisition and preprocessing, feature extraction procedures, OCR metrics, DEA configuration, Supplementary Tables S1–S8, and supplementary interpretation of DEA results.

    (DOCX)

    pone.0354277.s001.docx (35.6KB, docx)
    S2 Dataset. Minimal dataset underlying the findings of the study.

    This dataset contains raw image-derived variables, OCR-derived variables, clustering assignments, DEA input/output variables, and the values used to generate the reported figures and descriptive statistics reported in the manuscript.

    (ZIP)

    pone.0354277.s002.zip (62.5KB, zip)
    Attachment

    Submitted filename: Response to Reviewers.pdf

    pone.0354277.s004.pdf (109.5KB, pdf)
    Attachment

    Submitted filename: Rebuttal_Letter_221025.pdf

    pone.0354277.s005.pdf (80.5KB, pdf)
    Attachment

    Submitted filename: Response to Reviewers R2.docx

    pone.0354277.s006.docx (19.6KB, docx)
    Attachment

    Submitted filename: PLOS ONE review_.pdf

    pone.0354277.s007.pdf (883.5KB, pdf)
    Attachment

    Submitted filename: Response to Reviewers (Detailed Point-by-Point).pdf

    pone.0354277.s008.pdf (85.1KB, pdf)
    Attachment

    Submitted filename: Response_R4_map to_Track_Changes.docx

    pone.0354277.s009.docx (17.4KB, docx)
    Attachment

    Submitted filename: PLOS ONE review__.pdf

    pone.0354277.s010.pdf (887.2KB, pdf)
    Attachment

    Submitted filename: Response to Reviewers (PLOS ONE)_2026.pdf

    pone.0354277.s011.pdf (143.2KB, pdf)
    Attachment

    Submitted filename: PLOS ONE review_6.pdf

    pone.0354277.s012.pdf (1.4MB, pdf)
    Attachment

    Submitted filename: Response to Reviewer_R6.docx

    pone.0354277.s013.docx (14.5KB, docx)

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES